It's time to get another licensee but besides that, Abbott probably has already gotten the test on the analyzer or they would never have mentioned RECAF in the abstract for the July 24th conference. IMO, we will do fine with Abbott.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.